Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiprodil - Algernon Health

Next Previous
Drug Profile

Radiprodil - Algernon Health

Alternative Names: NP 121; RGH-896; UCB-3491

Latest Information Update: 23 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gedeon Richter
  • Developer Algernon Health; Forest Laboratories; Gedeon Richter; PRA Health Sciences; UCB
  • Class Antiepileptic drugs; Behavioural disorder therapies; Non-opioid analgesics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Idiopathic pulmonary fibrosis
  • Discontinued Epilepsy; Infantile spasms; Neuropathic pain; Pain; Parkinson's disease

Most Recent Events

  • 15 Oct 2025 Algernon Pharmaceuticals is now called Algernon Health
  • 28 Aug 2023 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Canada (PO)
  • 03 Jul 2019 Preclinical trials in Idiopathic pulmonary fibrosis in Canada before July 2019 (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top